Tian Lin Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tian Lin Xiao has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Chen Xin Deng
1 shared publicationFei Li
The ¶Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
1 shared publicationHaiquan Chen
The ¶Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
1 shared publication- Hongbin Ji
State Key Laboratory of Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China
1 shared publication Hua Qin Xie
1 shared publicationJia Yuan
1 shared publication
Latest Publications
- 28 September 2014
- Vol. 19 (3) , 812-8
Aggressive interventions in terminally ill patients with solid tumors in China: a retrospective single center analysis.
Overtreatment in terminally ill cancer patients is very common worldwide, but whether patients will benefit from aggressive care remains obscure. This study aimed to explore the value of aggressive interventions in the end of life in adult patients with advanced solid tumors. All adult patients who died from advanced solid tumors between 2011 and 2012 in Xiangyang Central Hospital were included. Detailed data concerning cancer types, therapy approach and outcome in the last three months of life were collected and assessed. 263 patients with median age 63 years died of cancer between 2011 and 2012. In the last 3 months of life, 82.5% of the patients received aggressive care, especially chemotherapy and radiotherapy. Traditional Chinese medicine was widely used. Median survival from diagnosis of metastasis to death was 6.9 months for patients treated with aggressive care and 6.2 months for the others, respectively (p>0.05). Despite their wide use, aggressive interventions in the last 3 months of life might have no benefit on survival. Radiotherapy provided significant symptom palliation of bone or brain metastases, but the short-course radiotherapy schedule was rarely used. Frequent reassessment of patients and making decision together with the patients is helpful to overcome the aggressive care. Appropriate tools to predict survival are needed to help design proper strategies for terminally ill cancer patients.
- 28 September 2014
- Vol. 19 (3) , 812-8
Aggressive interventions in terminally ill patients with solid tumors in China: a retrospective single center analysis.
Overtreatment in terminally ill cancer patients is very common worldwide, but whether patients will benefit from aggressive care remains obscure. This study aimed to explore the value of aggressive interventions in the end of life in adult patients with advanced solid tumors. All adult patients who died from advanced solid tumors between 2011 and 2012 in Xiangyang Central Hospital were included. Detailed data concerning cancer types, therapy approach and outcome in the last three months of life were collected and assessed. 263 patients with median age 63 years died of cancer between 2011 and 2012. In the last 3 months of life, 82.5% of the patients received aggressive care, especially chemotherapy and radiotherapy. Traditional Chinese medicine was widely used. Median survival from diagnosis of metastasis to death was 6.9 months for patients treated with aggressive care and 6.2 months for the others, respectively (p>0.05). Despite their wide use, aggressive interventions in the last 3 months of life might have no benefit on survival. Radiotherapy provided significant symptom palliation of bone or brain metastases, but the short-course radiotherapy schedule was rarely used. Frequent reassessment of patients and making decision together with the patients is helpful to overcome the aggressive care. Appropriate tools to predict survival are needed to help design proper strategies for terminally ill cancer patients.
- Open Access
- 1 June 2012
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 287 (27) , 23227-23235
MicroRNA-143 (miR-143) Regulates Cancer Glycolysis via Targeting Hexokinase 2 Gene
- 1 June 2012
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 287 (27) , 23227-23235
Open AccessMicroRNA-143 (miR-143) Regulates Cancer Glycolysis via Targeting Hexokinase 2 Gene